Straits Times Index
3,309.21 -12.87 (-0.39%) S&P 500
5,360.79 +13.80 (+0.26%) Dow
38,868.04 +69.05 (+0.18%) Nasdaq
17,192.53 +59.40 (+0.35%) Bitcoin USD
66,991.62 -2,345.25 (-3.38%) CMC Crypto 200
1,390.80 -50.84 (-3.53%)
Sedana Medical AB (publ) (SEDANA.ST)
| Previous close | 26.35 |
| Open | 26.00 |
| Bid | 25.65 x 0 |
| Ask | 25.80 x 0 |
| Day's range | 25.60 - 26.40 |
| 52-week range | 13.88 - 33.72 |
| Volume | |
| Avg. volume | 282,111 |
| Market cap | 2.548B |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Sedana Medical completes patient recruitment for its clinical program in the US
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 2 phase III clinical trial in the United States. Earlier this spring, Sedana Medical reported the completion of enrolment to the parallel phase III clinical trial INSPiRE-ICU 1. The company anticipates topline results from both trials in the second half of 2024, with a planned New Drug Application (NDA) submission in the first quarter of 2025.
- PR Newswire
Sedana Medical completes patient recruitment for INSPiRE-ICU 1 clinical trial in the US
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235 randomized patients remaining. The company anticipates topline results from both trials in the second half of 2024, with a planned New Drug Application (NDA) submission in the first quarter of 2025.
